Skip to main content
. 2024 Sep 26;2024(9):CD006689. doi: 10.1002/14651858.CD006689.pub3

8.20. Analysis.

8.20

Comparison 8: Mefloquine (MQ) versus daily cotrimoxazole (CTXp), Outcome 20: Adverse events: fatigue/weakness